DOCSLIB.ORG

Minimally Invasive Diagnosis of Endometriosis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Minimally Invasive Diagnosis of Endometriosis General articles Ref: Ro J Med Pract. 2021;16(1) DOI: 10.37897/RJMP.2021.1.5 Minimally invasive diagnosis of endometriosis Cătălina Diana STANICA, Adrian NEACSU, Romina Marina SIMA, Raluca Gabriela IOAN Departament of Obstetrics and Gynecology, ”Carol Davila” University of Medicine and Pharmacy, Bucharest Abstract Endometriosis is a common condition among women of reproductive age that can cause chronic pelvic pain and infertility. Rapid establishment of a positive diagnosis of endometriosis is essential for effective management. The positive diagnosis of endometriosis is difficult to establish and requires invasive methods. The "golden standard" for diagnosis is still laparoscopy. Current research has not yet established specific non-invasive diagnostic methods for endometriosis. Imaging techniques, endometrial or serum markers facilitate diagnosis and are useful in monitoring the patient's progress. A number of noninvasive investigations, such as imaging techniques, or biomarkers are currently being evaluated for use in routine practice. A combination of these noninvasive tests could be the standard for diagnosing endometriosis in the future. Keywords: endometriosis, noninvasive diagnosis, imaging diagnosis INTRODUCTION menstrual pain), infertility, dysuria, rectal tenesmus, hematuria, hemoptysis, the diagnosis of endometriosis Endometriosis is a common gynecological condi- should be considered. The symptoms have a cyclical tion, found in women of reproductive age, with impor- character, similar to the menstrual cycle (1). tant implications for their quality of life and married The positive diagnosis of endometriosis involves life. The costs involved in the diagnosis and treatment the use of invasive methods that allow the visualization of endometriosis, not negligible, have special so- of lesions and the taking of tissue samples from suspi- cio-economic consequences. cious lesions. The anatomo-pathological examination The exact pathophysiological mechanisms involved of the samples taken establishes the diagnosis of cer- in the onset and progression of the disease are not tainty. This is currently the „gold standard” in the diag- known. Endometriosis can be classified as adenomyo- nosis of endometriosis (2). There is currently no mini- sis (endometriosis developed in the thickness of the mally invasive paraclinical test to establish a definite myometrium) and endometriosis itself (development diagnosis of endomertiosis. Currently available investi- of ectopic endometrial tissue outside the uterus), with gations supplement only clinical data, strengthening genital or extragenital location, can affect the large in- the suspicion of the diagnosis of endometriosis and testine at different levels, appendix, urinary tract, res- also allowing monitoring of treatment. piratory tract brain, skin etc. About 10% of women of reproductive age suffer In the case of a woman of childbearing age who has from endometriosis, and recent epidemiological data chronic pelvic pain (dysmenorrhea, dyspareunia, inter- show an increase in the incidence of the disease (3). Corresponding author: Article History: Catalina Diana Stanica Received: 08 March 2021 E-mail: [email protected] Accepted: 16 March 2021 ROMANIAN JOURNAL OF MEDICAL PRACTICE – VOL. XVI, NO. 1 (75), 2021 25 ROMANIAN JOURNAL OF MEDICAL PRACTICE – VOL. XVI, NO. 1 (75), 2021 The condition affects a woman’s quality of life and re- (10,11). However, its sensitivity and specificity are low, productive potential, by decreasing fertility. The dis- with elevated plasma levels being found in other condi- covery of non-invasive diagnostic tests, of population tions (epithelial neoplasms, pericarditis, pancreatitis screening methods, which would allow the start of etc.). treatment from an early stage, would therefore be very Serological markers such as the antigens CA-72, CA useful. 15-3, CA 19-9, TAG-72 have not yet demonstrated their The development of imaging methods, the extraor- utility in the diagnosis of endometriosis (12-14). In the dinary advances registered in the field of genetics, of case of placental protein 14 (PP14) there is a very good the study of biological, cellular and molecular markers, correlation with the stage of the disease (15,16). Also, constitute premises for the discovery of new efficient the specificity for diagnosing endometriosis when de- methods of diagnosis and treatment in endometriosis. termining antiendometrial antibodies can reach almost 100% (17,18). OBJECTIVE AND METHOD In endometriosis, cytokines (19,20) appear to have a profound effect on the implantation of endometriotic The objective of this paper was to identify in the sources by reducing immunological surveillance and literature new minimally invasive methods for diagnos- identifying and destroying endometrial cells. Of these, ing endometriosis. IL-6 has been the most studied in recent decades, with We searched in electronic databases (PubMed, good sensitivity and specificity. However, it is better Google Scholar) articles and clinical studies published that future studies focus on the diagnostic efficacy of in recent years, which identify minimally invasive meth- IL-6 combined with other cytokines. ods for diagnosing endometriosis. We selected only In an attempt to pinpoint the existence and location the materials that specify that they went through the of endometriotic implants as accurately and less inva- peer review procedure. sively as possible, the use as markers of substances that specifically combine with surface receptors of ec- BIOMARKERS USED TO DETECT topic endometrial tissue is tested. Laser-induced lumi- nescence is based on the fact that a tissue, exposed to ENDOMETRIOSIS light of a certain wavelength, emits fluorescence in a The definite diagnosis of endometriosis still involves specific spectrum, as well as some tissue-specific drugs. invasive techniques (laparoscopy and laparotomy). It was found that tamoxifen has the best concentration Current research seeks to establish non-invasive, relia- in endometriotic implants, its highlighting can be done ble, relatively low-cost methods for diagnosing endo- with an argon-ion laser (21). A similar method is based metriosis. on the use of 5-aminolevulinic acid that accumulates in Understanding the pathophysiological mechanisms endometriotic tissue, where it is converted to pro- involved in the onset and progression of endometriosis toporphyrin IX, which has the ability to emit fluores- has led to the study of a large number of possible bio- cent (22). logical, cellular or molecular markers that could have There are studies of monoclonal antibodies that practical utility in the diagnosis of endomertiosis (4,5). bind specifically to target endometriotic cells that facil- Hormonal, immunological mechanisms are studied, itate the definite diagnosis of endometriosis, but also which involve adhesion molecules and cellular recep- open up new therapeutic options for the use of cyto- tors, as well as biochemical changes in the eutopic or toxic substances or inhibitors of ectopic endometrial ectopic endometrium. Many of the studies have had activity related to these “carrier” (23). promising results in animal or in vitro models, not in Studies have found that miRNAs obtained from dis- human patient studies, but research is ongoing. eased tissues and other body fluids have been able to In recent years, a number of serological markers, detect various diseases (24). MiRNA deregulation is in- peritoneal fluid, or menstrual flow have been studied volved in the pathophysiology of endometriosis and (6-9). has been investigated as potential biomarkers, howev- The most widely used serological marker today is er additional validations in a large population using a the CA-125 antigen. This is a high molecular weight sur- standardized reproducible methodology to further face glycoprotein (20 Kilodaltons), whose serum con- clarify the diagnostic potential of miRNAs. centration increases in women with endometriosis, There are studies on the altered expression of cer- correlated with the stage of the disease. The marker is tain genes in endometriotic implants, or protein sub- useful in monitoring treatment (values decrease after sets secreted by ectopic endometrial tissue (25-27). administration of danazol or GnRh agonists), or in mon- Out of a total number of 4,133 genes studied, 8 genes itoring the recurrence of post-therapeutic disease were identified as altered in endometriotic tissue. 26 ROMANIAN JOURNAL OF MEDICAL PRACTICE – VOL. XVI, NO. 1 (75), 2021 IMAGING METHODS FOR DIAGNOSING Another useful investigation in the positive diagno- ENDOMETRIOSIS sis of endomeriosis is sonohisterography. This was pro- posed for further study of salpinges (41), being a com- The two-dimensional transvaginal ultrasound ex- bination of transvaginal ultrasound and instillation into amination proved to be very useful in detecting ovarian the uterine cavity of a saline or opaque solution follow- endometriomas with a diameter greater than 10 mm, ing the passage of its tubal passage and the appear- but also in differentiating them from other adnexal ance of fluid in the bottom of the Douglas sac. Sono- masses, as well as in following their evolution under histerography is useful in differentiating endometriosis drug treatment. adenomyosis and in investigating tubal infertility, being The cystic character with homogeneous hypoechoic an alternative to hysterosalpingography. appearance, with the presence of echoes of low inten- Ultrasound remains the initial choice in the assess-
Load more

Recommended publications
  • 2021 – the Following CPT Codes Are Approved for Billing Through Women’S Way
    WHAT’S COVERED – 2021 Women’s Way CPT Code Medicare Part B Rate List Effective January 1, 2021 For questions, call the Women’s Way State Office 800-280-5512 or 701-328-2389 • CPT codes that are specifically not covered are 77061, 77062 and 87623 • Reimbursement for treatment services is not allowed. (See note on page 8). • CPT code 99201 has been removed from What’s Covered List • New CPT codes are in bold font. 2021 – The following CPT codes are approved for billing through Women’s Way. Description of Services CPT $ Rate Office Visits New patient; medically appropriate history/exam; straightforward decision making; 15-29 minutes 99202 72.19 New patient; medically appropriate history/exam; low level decision making; 30-44 minutes 99203 110.77 New patient; medically appropriate history/exam; moderate level decision making; 45-59 minutes 99204 165.36 New patient; medically appropriate history/exam; high level decision making; 60-74 minutes. 99205 218.21 Established patient; evaluation and management, may not require presence of physician; 99211 22.83 presenting problems are minimal Established patient; medically appropriate history/exam, straightforward decision making; 10-19 99212 55.88 minutes Established patient; medically appropriate history/exam, low level decision making; 20-29 minutes 99213 90.48 Established patient; medically appropriate history/exam, moderate level decision making; 30-39 99214 128.42 minutes Established patient; comprehensive history exam, high complex decision making; 40-54 minutes 99215 128.42 Initial comprehensive
    [Show full text]
  • New Patient Paperwork: Women
    The Texas Center for Reproductive Acupuncture ______________________________________________________________ Patient Intake Form: Women __________________________________________________________________________________________________________________________________________________________________________________________________________________ Important: The information on this form will help your acupuncturist to give you the best and most comprehensive care possible. It is important for you to complete this document as thoroughly as possible. Even though some of the questions may seem completely unrelated to your condition, they may play a contributing, or underlying role in diagnosis and treatment of your problem. __________________________________________________________________________________________________________________________________________________________________________________________________________________ General Patient Information (All of the information provided is strictly confidential – see permission to share medical information section) Last Name: _____________________________ First Name: _______________________________ Middle Initial: _______ Age: ______ Primary Telephone Number: ____________________________________ Alternative Phone # ______________________________________ E-Mail: ____________________________________ Date of Birth ____ / _____ / _____ Today’s Date ___/___/_____ Number of Name of your Menstrual Cycle Pregnancies Age menstruation began: _______ Cesarean Births Ob/Gyn: __________________________________________
    [Show full text]
  • Colposcopy.Pdf
    CCololppooscoscoppyy ► Chris DeSimone, M.D. ► Gynecologic Oncology ► Images from Colposcopy Cervical Pathology, 3rd Ed., 1998 HistoHistorryy ► ColColpposcopyoscopy wwasas ppiioneeredoneered inin GGeermrmaanyny bbyy DrDr.. HinselmannHinselmann dduriurinngg tthhee 19201920’s’s ► HeHe sousougghtht ttoo prprooveve ththaatt micmicrroscopicoscopic eexaminxaminaationtion ofof thethe cervixcervix wouwoulldd detectdetect cervicalcervical ccancanceerr eeararlliierer tthhaann 44 ccmm ► HisHis workwork identidentiifiefiedd severalseveral atatyypicalpical appeappeararanancceses whwhicichh araree stistillll usedused ttooddaay:y: . Luekoplakia . Punctation . Felderung (mosaicism) Colposcopy Cervical Pathology 3rd Ed. 1998 HistoHistorryy ► ThrThrooughugh thethe 3030’s’s aanndd 4040’s’s brbreaeaktkthrhrouougghshs wwereere mamaddee regregaarrddinging whwhicichh aapppepeararancanceess wweerere moremore liklikelelyy toto prprogogressress toto invinvaasivesive ccaarcinomrcinomaa;; HHOOWEWEVVERER,, ► TheThessee ffiinndingsdings wweerere didifffficiculultt toto inteinterrpretpret sincesince theythey werweree notnot corcorrrelatedelated wwithith histologhistologyy ► OneOne resreseaearcrchherer wwouldould claclaiimm hhiiss ppatatientsients wwithith XX ffindindiingsngs nevernever hahadd ccaarcinomarcinoma whwhililee aannothotheerr emphemphaatiticcallyally belibelieevedved itit diddid ► WorldWorld wiwidede colposcopycolposcopy waswas uunnderderuutitillizizeedd asas aa diadiaggnosticnostic tooltool sseeconcondadaryry ttoo tthheseese discrepadiscrepannciescies HistoHistorryy
    [Show full text]
  • Cervical Cancer Risk Factors and Feasibility of Visual Inspection with Acetic Acid Screening in Sudan
    International Journal of Women’s Health Dovepress open access to scientific and medical research Open Access Full Text Article RAPID CommUNicatioN Cervical cancer risk factors and feasibility of visual inspection with acetic acid screening in Sudan Ahmed Ibrahim1 Objectives: To assess the risk factors of cervical cancer and the feasibility and acceptability Vibeke Rasch2 of a visual inspection with acetic acid (VIA) screening method in a primary health center in Eero Pukkala3 Khartoum, Sudan. Arja R Aro1 Methods: A cross-sectional prospective pilot study of 100 asymptomatic women living in Khartoum State in Sudan was carried out from December 2008 to January 2009. The study was 1Unit for Health Promotion Research, University of Southern Denmark, performed at the screening center in Khartoum. Six nurses and two physicians were trained Esbjerg, Denmark; 2Department by a gynecologic oncologist. The patients underwent a complete gynecological examination of Obstetrics and Gynecology, and filled in a questionnaire on risk factors and feasibility and acceptability. They were screened Odense University Hospital, Odense, Denmark; 3Institute for Statistical for cervical cancer by application of 3%–5% VIA. Women with a positive test were referred For personal use only. and Epidemiological Cancer Research, for colposcopy and treatment. Finnish Cancer Registry, Helsinki, Sixteen percent of screened women were tested positive. Statistically significant Finland Results: associations were observed between being positive with VIA test and the following variables: uterine cervix laceration (odds ratio [OR] 18.6; 95% confidence interval [CI]: 4.64–74.8), assisted vaginal delivery (OR 13.2; 95% CI: 2.95–54.9), parity (OR 5.78; 95% CI: 1.41–23.7), female genital mutilation (OR 4.78; 95% CI: 1.13–20.1), and episiotomy (OR 5.25; 95% CI: 1.15–23.8).
    [Show full text]
  • Estimation of a Lower Bound for the Cumulative Incidence of Failure Of
    CHAPTER 1 Introduction 11 1.1 Background The incidence of failure of a method for contraception is generally a matter of great interest to any person who uses, or whose sexual partner uses, that method. Not surprisingly, there is a large volume of research into the failure rates of all of the temporary methods for human contraception. However, there is a much more modest literature on the cumulative incidence of failure and annual failure rates of permanent sterilisation, particularly failures of female tubal sterilisation - often called “tubal ligation”, but including any means for occluding or interrupting the Fallopian tubes by surgical means. This is somewhat surprising given that female tubal sterilisation remains one of the most popular and widely used means of contraception. The Australian Study of Health and Relationships, which was conducted between May 2001 and June 2002 using a representative sample of 9,134 women aged 16 to 59 years, found that of the two-thirds of respondents who reported using some form of contraception, 22.5 per cent relied on tubal ligation or hysterectomy (these were not further distinguished), which was second in popularity only to oral contraceptives.1 The proportion of women in the 40-49 year age group who relied on tubal ligation or hysterectomy was 33 per cent, which was second in popularity only to vasectomy in the partner (34.6 per cent). In the 1995 United States Survey of Family Growth, conducted by the US National Center for Health Statistics, surgical sterilisation was the method of choice in
    [Show full text]
  • Co-Registered Multimodal Endoscope for Early Ovarian Cancer by David
    Co-registered Multimodal Endoscope for Early Ovarian Cancer by David Vega __________________________ Copyright © David Vega 2021 A Dissertation Submitted to the Faculty of the WYANT COLLEGE OF OPTICAL SCIENCES In Partial Fulfillment of the Requirements For the Degree of DOCTOR OF PHILOSOPHY In the Graduate College THE UNIVERSITY OF ARIZONA 2021 *$$)*&+!"**)++"&%&$$"++.)+"/+!+.!-)+!"**)++"&% ')')/ +"+# %)&$$%+!+"+'+*,#"##"% +!"**)++"&%)(,")$%+&)+! )&&+&)&!"#&*&'!/ +05/14/2021 + 05/14/2021 + "%#'')&-#%'+%&+!"*"**)++"&%"*&%+"% %+,'&%+!%"+0**,$"**"&% &+!"%#&'"*&+!"**)++"&%+&+! ),+&## !)/)+"/+!+ !-)+!"*"**)++"&%')'),%)$/")+"&%%)&$$% +!+"+'+*,#"##"% +!"**)++"&%)(,")$%+ +05/14/2021 "**)++"&%&$$"++!") 3 STATEMENT BY AUTHOR This dissertation has been submitted in partial fulfillment of the requirements for an advanced degree at the University of Arizona and is deposited in the University Library to be made available to borrowers under rules of the Library. Brief quotations from this dissertation are allowable without special permission, provided that an accurate acknowledgement of the source is made. Requests for permission for extended quotation from or reproduction of this manuscript in whole or in part may be granted by the head of the major department or the Dean of the Graduate College when in his or her judgment the proposed use of the material is in the interests of scholarship. In all other instances, however, permission must be obtained from the author. SIGNED: David Vega 4 DEDICATION A mi familia.
    [Show full text]
  • Colposcopy of the Uterine Cervix
    THE CERVIX: Colposcopy of the Uterine Cervix • I. Introduction • V. Invasive Cancer of the Cervix • II. Anatomy of the Uterine Cervix • VI. Colposcopy • III. Histology of the Normal Cervix • VII: Cervical Cancer Screening and Colposcopy During Pregnancy • IV. Premalignant Lesions of the Cervix The material that follows was developed by the 2002-04 ASCCP Section on the Cervix for use by physicians and healthcare providers. Special thanks to Section members: Edward J. Mayeaux, Jr, MD, Co-Chair Claudia Werner, MD, Co-Chair Raheela Ashfaq, MD Deborah Bartholomew, MD Lisa Flowers, MD Francisco Garcia, MD, MPH Luis Padilla, MD Diane Solomon, MD Dennis O'Connor, MD Please use this material freely. This material is an educational resource and as such does not define a standard of care, nor is intended to dictate an exclusive course of treatment or procedure to be followed. It presents methods and techniques of clinical practice that are acceptable and used by recognized authorities, for consideration by licensed physicians and healthcare providers to incorporate into their practice. Variations of practice, taking into account the needs of the individual patient, resources, and limitation unique to the institution or type of practice, may be appropriate. I. AN INTRODUCTION TO THE NORMAL CERVIX, NEOPLASIA, AND COLPOSCOPY The uterine cervix presents a unique opportunity to clinicians in that it is physically and visually accessible for evaluation. It demonstrates a well-described spectrum of histological and colposcopic findings from health to premalignancy to invasive cancer. Since nearly all cervical neoplasia occurs in the presence of human papillomavirus infection, the cervix provides the best-defined model of virus-mediated carcinogenesis in humans to date.
    [Show full text]
  • Obstetrics and Gynecology Clinical Privilege List
    Obstetrics and Gynecology Clinical Privilege List Description of Service Alberta Health Services (AHS) Medical Staff who are specialists in Obstetrics and Gynecology (or its associated subspecialties) and have privileges in the Department of Obstetrics and Gynecology provide safe, high quality care for obstetrical and gynecologic patients in AHS facilities across the province. The specialty encompasses medical, surgical, obstetrical and gynecologic knowledge and skills for the prevention, diagnosis and management of a broad range of conditions affecting women's gynecological and reproductive health. Working to provide a patient-focused, quality health system that is accessible and sustainable for all Albertans, the department also offers subspecialty care including gynecological oncology, reproductive endocrinology, maternal fetal medicine, urogynecology, and minimally invasive surgery.1 Obstetrics and Gynecology privileges may include admitting, evaluating, diagnosing, treating (medical and/or surgical management), to female patients of all ages presenting in any condition or stage of pregnancy or female patients presenting with illnesses, injuries, and disorders of the gynecological or genitourinary system including the ability to assess, stabilize, and determine the disposition of patients with emergent conditions consistent with medical staff policy regarding emergency and consultative call services. Providing consultation based on the designated position profile (clinical; education; research; service), and/or limited Medical Staff
    [Show full text]
  • American Society for Colposcopy and Cervical Pathology
    American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the Prevention and Early Detection of Cervical Cancer Debbie Saslow, PhD,1 Diane Solomon, MD,2 Herschel W. Lawson, MD,3 Maureen Killackey, MD,4 Shalini L. Kulasingam, PhD,5 Joanna Cain, MD, FACOG,6 Francisco A. R. Garcia, MD, MPH,7 Ann T. Moriarty, MD,8 Alan G. Waxman, MD, MPH,9 David C. Wilbur, MD,10 Nicolas Wentzensen, MD, PhD, MS,11 Levi S. Downs, Jr, MD,12 Mark Spitzer, MD,13 Anna-Barbara Moscicki, MD,14 Eduardo L. Franco, DrPH,15 Mark H. Stoler, MD,16 Mark Schiffman, MD,17 Philip E. Castle, PhD, MPH,18* and Evan R. Myers, MD, MPH19* 1Director, Breast and Gynecologic Cancer, Cancer Control Science Department, American Cancer Society, Atlanta, GA, on behalf of the Steering Committee, Data Group, and Writing Committee; 2Senior Investigator, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Rockville, MD, on behalf of the Steering Committee; 3Adjunct Associate Professor, Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, GA, on behalf of the Data Group; 4Deputy Physician in Chief, Medical Director, Memorial Sloan-Kettering Cancer Center Regional Network, Department of Surgery, Gynecology Service, Memorial Sloan-Kettering Cancer Center, Correspondence to: Debbie Saslow, PhD, Director, Breast and Gyneco- Disclaimers: The contents of the paper are solely the responsibility of logic Cancer, American Cancer Society, 250 Williams St NW, Suite 600, the authors and do not necessarily represent the official views of the Atlanta, GA 30303.
    [Show full text]
  • Download Download
    Medical Research Archives. Volume 5, issue 6. June 2017. The evolution of gynecologic endoscopic surgery over 50 years – a pleasant adventure The evolution of gynecologic endoscopic surgery over 50 years – a pleasant adventure Author Liselotte Mettler Department of Obstetrics Abstract: and Gynaecology, Endoscopic surgery spans the wings from 1901 (Georg Kelling) till the cutting edge years with Raoul Palmer, Kurt University Hospitals Semm , Hans Frangenheim , Hans Lindemann and Jordan Schleswig-Holstein, Philipps in 1985 in gynecology , It did experience further multispecialitxy progress from 1985 – 2017 with higher Arnold-Heller-Str. 3, dexterity, precision , loss of anxiety, micro and robotic House 24, 24105 Kiel, surgery, single , multiple ports and robotic technology. The evolution has just begun and will lead to a bright future. The Campus Kiel, Germany, influence of industry, which has kept pace and actively Email: supported this development for years, is the driving force besides the heroes of doctors and engineers that bring up new [email protected] ideas. Without suitable technology, this dissemination would 1 Copyright 2017 KEI Journals. All Rights Reserved. Medical Research Archives. Volume 5, issue 6. June 2017. The evolution of gynecologic endoscopic surgery over 50 years – a pleasant adventure not have been possible. Endoscopic development and its future does depend on new inventions, on the audacity of leading heroes, their input into this field but also on their management of life to continue to survive and on a healthy and successful cooperation with the medical technical industry and the governments of our countries which grant us the freedom of research and development for the best of all our patients.
    [Show full text]
  • UNMH Obstetrics and Gynecology Clinical Privileges Name
    UNMH Obstetrics and Gynecology Clinical Privileges Name:____________________________ Effective Dates: From __________ To ___________ All new applicants must meet the following requirements as approved by the UNMH Board of Trustees, effective April 28, 2017: Initial Privileges (initial appointment) Renewal of Privileges (reappointment) Expansion of Privileges (modification) INSTRUCTIONS: Applicant: Check off the “requested” box for each privilege requested. Applicants have the burden of producing information deemed adequate by the Hospital for a proper evaluation of current competence, current clinical activity, and other qualifications and for resolving any doubts related to qualifications for requested privileges. Department Chair: Check the appropriate box for recommendation on the last page of this form. If recommended with conditions or not recommended, provide condition or explanation. OTHER REQUIREMENTS: 1. Note that privileges granted may only be exercised at UNM Hospitals and clinics that have the appropriate equipment, license, beds, staff, and other support required to provide the services defined in this document. Site-specific services may be defined in hospital or department policy. 2. This document defines qualifications to exercise clinical privileges. The applicant must also adhere to any additional organizational, regulatory, or accreditation requirements that the organization is obligated to meet. ---------------------------------------------------------------------------------------------------------------------------------------
    [Show full text]
  • SJH Procedures
    SJH Procedures - Gynecology and Gynecology Oncology Services New Name Old Name CPT Code Service ABLATION, LESION, CERVIX AND VULVA, USING CO2 LASER LASER VAPORIZATION CERVIX/VULVA W CO2 LASER 56501 Destruction of lesion(s), vulva; simple (eg, laser surgery, Gynecology electrosurgery, cryosurgery, chemosurgery) 56515 Destruction of lesion(s), vulva; extensive (eg, laser surgery, Gynecology electrosurgery, cryosurgery, chemosurgery) 57513 Cautery of cervix; laser ablation Gynecology BIOPSY OR EXCISION, LESION, FACE AND NECK EXCISION/BIOPSY (MASS/LESION/LIPOMA/CYST) FACE/NECK General, Gynecology, Plastics, ENT, Maxillofacial BIOPSY OR EXCISION, LESION, FACE AND NECK, 2 OR MORE EXCISE/BIOPSY (MASS/LESION/LIPOMA/CYST) MULTIPLE FACE/NECK 11102 Tangential biopsy of skin (eg, shave, scoop, saucerize, curette); General, Gynecology, single lesion Aesthetics, Urology, Maxillofacial, ENT, Thoracic, Vascular, Cardiovascular, Plastics, Orthopedics 11103 Tangential biopsy of skin (eg, shave, scoop, saucerize, curette); General, Gynecology, each separate/additional lesion (list separately in addition to Aesthetics, Urology, code for primary procedure) Maxillofacial, ENT, Thoracic, Vascular, Cardiovascular, Plastics, Orthopedics 11104 Punch biopsy of skin (including simple closure, when General, Gynecology, performed); single lesion Aesthetics, Urology, Maxillofacial, ENT, Thoracic, Vascular, Cardiovascular, Plastics, Orthopedics 11105 Punch biopsy of skin (including simple closure, when General, Gynecology, performed); each separate/additional lesion
    [Show full text]